Most people recover from norovirus, a highly contagious infection, within a few days but it can be particularly risky for ...

The Phase 1 trial is an open label, dose ranging clinical study designed to evaluate Vaxart’s second-generation oral norovirus vaccine constructs head-to-head against its first-generation constructs.

In an early clinical trial, an experimental norovirus vaccine given as a pill produced defensive responses exactly where it counts—in the saliva of older people most vulnerable to the explosive ...

Researchers at Vaxart Inc. and the Center for Vaccine Development at the University of Maryland School of Medicine evaluated ...

Norovirus has torn through the U.S. this winter, peaking early in some parts of the country but taking hold in South Florida ...

HEALTH chiefs have warned winter “is certainly not over” with norovirus hospitalisations still close to record highs – and ...

The finding could lead to the design of broadly effective norovirus vaccine, as well as the development of new therapeutic antibodies for the treatment of norovirus-associated gastroenteritis.

WHILE norovirus still circulates at high levels, a new pill designed to protect against the winter vomiting bug has been undergoing trials. Just two weeks ago there was a record number of patients ...

Vaxart (NASDAQ:VXRT – Get Free Report) is expected to release its earnings data before the market opens on Thursday, March ...

Vaxart (VXRT) announced the initiation of a Phase 1, open label, dose ranging clinical trial evaluating its second-generation oral norovirus ...

An early trial of a norovirus vaccine pill has shown promise at protecting against the notorious “winter vomiting” bug, with researchers saying it could potentially be available for use in a ...

Researchers at Vaxart Inc. and the Center for Vaccine Development at the University of Maryland School of Medicine evaluated the safety and immunogenicity of an oral norovirus vaccine tablet ...